SKYSCAPER-01 – a phase III trial of tiragolumab (anti-TIGIT antibody) and atezolizumab (anti-PD-L1 antibody) in unresectable stage 4 NSCLC had a negative co-primary endpoint of PFS, while the phase III trial SKYSCRAPER-02 also failed to find PFS or OS benefits from Tiragolumab in patients with extensive-stage small cell lung cancer (SCLC) [20, 21]. The gene discussed is CD274; the disease is small cell lung carcinoma.